Bottom Line Up Front
MSC therapy for peripheral neuropathy (diabetic, idiopathic, or chemotherapy-induced) is at the very earliest evidence stage — Level 4. Published data consists primarily of preclinical studies and limited case reports. What MSCs may do: reduce neuroinflammation and support nerve regeneration pathways. What they cannot do: reverse structural nerve death or restore function in severely damaged nerves. Patients should approach this application with extreme caution and realistic expectations.
Evidence Level: Level 4 (Very Early)
Mostly preclinical (animal) studies with limited human case reports. No comparative studies or randomized trials. This is an area of active research, not clinical practice supported by robust evidence.
Peripheral neuropathy — numbness, tingling, burning pain, and loss of sensation in the hands and feet — affects approximately 20 million Americans. Diabetic neuropathy is the most common form. Current treatments manage symptoms (gabapentin, pregabalin, duloxetine) but do not repair damaged nerves. This unmet need drives patient interest in regenerative approaches.
Honest Assessment
If you are considering MSC therapy for neuropathy, understand that you are pursuing an experimental treatment with very limited human evidence. Any clinic that promises nerve regeneration or restoration of sensation for neuropathy is far ahead of what the published science supports. A responsible clinic will frame this as exploratory, discuss what is known and unknown, and not charge a premium price for a Level 4 evidence treatment.
Exploring Options for Neuropathy?
We'll connect you with a clinic that is honest about the evidence and realistic about what MSC therapy may offer for nerve conditions.
Get Free Consultation